Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.